User menu

MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?

Bibliographic reference Hav, Monirath ; Libbrecht, Louis ; Ferdinande, Liesbeth ; Pattyn, Piet ; Laurent, Stephanie ; et. al. MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?. In: Virchows Archiv : an international journal of pathology, Vol. 458, no.2, p. 197-203 (2011)
Permanent URL
  1. Farnebo Marianne, Bykov Vladimir J.N., Wiman Klas G., The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer, 10.1016/j.bbrc.2010.02.152
  2. Ventura Andrea, Kirsch David G., McLaughlin Margaret E., Tuveson David A., Grimm Jan, Lintault Laura, Newman Jamie, Reczek Elizabeth E., Weissleder Ralph, Jacks Tyler, Restoration of p53 function leads to tumour regression in vivo, 10.1038/nature05541
  3. Qian Y, Chen X (2010) Tumor suppression by p53: making cells senescent. Histol Histopathol 25(4):515–526
  4. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y (2009) Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 219(1):3–15
  5. Momand J, The MDM2 gene amplification database, 10.1093/nar/26.15.3453
  6. Forslund A., Zeng Z., Qin L.-X., Rosenberg S., Ndubuisi M., Pincas H., Gerald W., Notterman D. A., Barany F., Paty P. B., MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers, 10.1158/1541-7786.mcr-07-0239
  7. Spiessl B, Beahrs OH, Hermanek P et al (1992) UICC—TNM atlas. 3rd ed. 2nd Rev. Springer-Verlag, Berlin
  8. Haupt Ygal, Maya Ruth, Kazaz Anat, Oren Moshe, Mdm2 promotes the rapid degradation of p53, 10.1038/387296a0
  9. Honda Reiko, Tanaka Hirofumi, Yasuda Hideyo, Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53, 10.1016/s0014-5793(97)01480-4
  10. Oliner Jonathan D., Pietenpol Jennifer A., Thiagalingam Sam, Gyuris Jeno, Kinzler Kenneth W., Vogelstein Bert, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, 10.1038/362857a0
  11. Jones Stephen N., Roe Amy E., Donehower Lawrence A., Bradley Allan, Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53, 10.1038/378206a0
  12. de Oca Luna Roberta Montes, Wagner Daniel S., Lozano Guillermina, Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53, 10.1038/378203a0
  13. Bond Gareth L., Hu Wenwei, Bond Elisabeth E., Robins Harlan, Lutzker Stuart G., Arva Nicoleta C., Bargonetti Jill, Bartel Frank, Taubert Helge, Wuerl Peter, Onel Kenan, Yip Linwah, Hwang Shih-Jen, Strong Louise C., Lozano Guillermina, Levine Arnold J., A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans, 10.1016/j.cell.2004.11.022
  14. Grochola Lukasz F., Müller Thomas H., Bond Gareth L., Taubert Helge, Udelnow Andrej, Würl Peter, MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation : , 10.1097/mpa.0b013e3181b9f105
  15. Onel K, Cordon-Cardo C (2004) MDM2 and prognosis. Mol Cancer Res 2(1):1–8
  16. Weaver Joshua, Downs-Kelly Erinn, Goldblum John R, Turner Sondra, Kulkarni Sucheta, Tubbs Raymond R, Rubin Brian P, Skacel Marek, Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms, 10.1038/modpathol.2008.84
  17. Schiebe Martina, Ohneseit Petra, Hoffmann Wolfgang, Meyermann R., Rodemann Hans-Peter, Bamberg Michael, 10.1023/a:1006410702284
  18. Vanden Bempt Isabelle, Van Loo Peter, Drijkoningen Maria, Neven Patrick, Smeets Ann, Christiaens Marie-Rose, Paridaens Robert, De Wolf-Peeters Christiane, Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing, 10.1200/jco.2007.13.4296
  19. Vassilev Lyubomir T., MDM2 inhibitors for cancer therapy, 10.1016/j.molmed.2006.11.002
  20. Vassilev L. T., In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2, 10.1126/science.1092472
  21. Shangary S., Qin D., McEachern D., Liu M., Miller R. S., Qiu S., Nikolovska-Coleska Z., Ding K., Wang G., Chen J., Bernard D., Zhang J., Lu Y., Gu Q., Shah R. B., Pienta K. J., Ling X., Kang S., Guo M., Sun Y., Yang D., Wang S., Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition, 10.1073/pnas.0708917105
  22. Shangary Sanjeev, Wang Shaomeng, Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy, 10.1146/annurev.pharmtox.48.113006.094723
  23. Dickens Michael P., Fitzgerald Ross, Fischer Peter M., Small-molecule inhibitors of MDM2 as new anticancer therapeutics, 10.1016/j.semcancer.2009.10.003
  24. Azmi Asfar S., Aboukameel Amro, Banerjee Sanjeev, Wang Zhiwei, Mohammad Momin, Wu Jack, Wang Shaomeng, Yang Dajun, Philip Philip A., Sarkar Fazlul H., Mohammad Ramzi M., MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function, 10.1016/j.ejca.2010.01.015
  25. Azmi A.S., Philip P.A., Aboukameel A., Wang Z., Banerjee S., Zafar S.F., Goustin A.-S., Almhanna K., Yang D., Sarkar F.H., Mohammad R.M., Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy, 10.2174/156800910791190229
  26. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B. T., Qing W., Packman K., Myklebost O., Heimbrook D. C., Vassilev L. T., Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy, 10.1073/pnas.0507493103
  27. Bond G. L, Menin C., Bertorelle R., Alhopuro P., Aaltonen L. A, Levine A. J, MDM2 SNP309 accelerates colorectal tumour formation in women, 10.1136/jmg.2006.043539
  28. Bond Gareth L., Hirshfield Kim M., Kirchhoff Tomas, Alexe Gabriella, Bond Elisabeth E., Robins Harlan, Bartel Frank, Taubert Helge, Wuerl Peter, Hait William, Toppmeyer Deborah, Offit Kenneth, Levine Arnold J., MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner, 10.1158/0008-5472.can-06-0180
  29. Ohtsubo Chihiro, Shiokawa Daisuke, Kodama Masami, Gaiddon Christian, Nakagama Hitoshi, Jochemsen Aart G., Taya Yoichi, Okamoto Koji, Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2, 10.1111/j.1349-7006.2009.01180.x
  30. Broll R, Stark A, Windhövel U, Best R, Strik M.W, Schimmelpenning H, Schwandner O, Kujath P, Bruch H.-P, Duchrow M, Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas, 10.1016/s0959-8049(99)00058-1
  31. Lam K Y, The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas, 10.1136/jcp.54.6.443
  32. Hori1 M, Shimazaki1 J, Inagawa1 S et al (2002) Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat 71:77–84
  33. Hao X. P., Gunther T., Roessner A., Price A. B., Talbot I. C., Expression of mdm2 and p53 in epithelial neoplasms of the colorectum, 10.1136/mp.51.1.26